Overview
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Status:
Completed
Completed
Trial end date:
2003-11-01
2003-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver radiation to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of radiation and chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy plus etoposide followed by peripheral stem cell transplantation in treating patients who have advanced myelodysplastic syndrome or refractory leukemia.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Memorial Sloan Kettering Cancer CenterCollaborator:
National Cancer Institute (NCI)Treatments:
Antibodies
Antibodies, Monoclonal
Etoposide
Etoposide phosphate
Immunoglobulins
Criteria
DISEASE CHARACTERISTICS:- One of the following diagnoses:
- Acute myeloid leukemia
- Accelerated/blastic phase of a myeloproliferative disorder (i.e., greater than
10% blasts in bone marrow or presence of extramedullary disease)
- Myelodysplastic syndrome
- Acute lymphocytic leukemia with expression of CD33
- Greater than 20% blast population
- No evidence of CNS disease
- Relapsed after previously achieving complete remission
- Must have previously had peripheral blood stem cells or bone marrow cells harvested
and cryopreserved while in remission
- Greater than 25% of bone marrow blasts must be CD33 positive
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 60 mL/min
Cardiovascular:
- LVEF greater than 50% by ECG or MUGA
- No history of cardiomyopathy or symptomatic congestive heart failure
Pulmonary:
- DLCO at least 50% predicted
Other:
- Not pregnant or nursing
- Negative pregnancy test
- HIV negative
- No other concurrent active malignancy
- No known sensitivity to E. coli derived products
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified